A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

NCT00211029 · clinicaltrials.gov ↗

COMPLETED

Status

4670

Enrollment

INDUSTRY

Sponsor class

Conditions

Red-Cell Aplasia, Pure

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.